Last reviewed · How we verify
Sequential Clomiphene citrate and Gonadotropin
Sequential Clomiphene citrate and Gonadotropin, marketed by Mansoura University, is a fertility treatment with a key composition patent expiring in 2028. The drug leverages a well-established mechanism to address primary indications, though specific revenue figures are not disclosed. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Sequential Clomiphene citrate and Gonadotropin |
|---|---|
| Also known as | Sequential Clomid and Menogon |
| Sponsor | Mansoura University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients (PHASE4)
- HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients
- Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: